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Revascularization after myocardial infarction is often achieved via percutaneous coronary intervention, which often entails
stenting. Drug-eluting stents have shown beneﬁts over bare metal stents in this setting, and a variety of drug-eluting stents are
now available, including sirolimus-, paclitaxel-, and zotarolimus-eluting stents. There are studies that have compared the various
drug-eluting stents and this meta-analysis pools data comparing 12-month clinical outcomes of zotarolimus- and paclitaxel-
eluting stents. End points studied were myocardial infarction, major adverse cardiac events, cardiac death, all-cause death, stent
thrombosis, target vessel revascularization, and target lesion revascularization.There was a statistically signiﬁcant reduction in
risk of myocardial infarction (odds ratio, 0.250, conﬁdence interval, 0.160 to 0.392) and statistically insigniﬁcant reductions in
major adverse cardiac events (odds ratio, 0.813, conﬁdence interval, 0.656 to 1.007), cardiac death (odds ratio, 0.817, conﬁdence
interval, 0.359 to 1.857), all cause death (odds ratio, 0.820, conﬁdence interval, 0.443 to 1.516), and target lesion revascularization
(odds ratio,0.936,conﬁdenceinterval 0.702 to 1.247).There wasa statisticallysigniﬁcantincreasein target vessel revascularization
(odds ratio, 1.336, conﬁdence interval, 1.003 to 1.778) and a statistically insigniﬁcant increase in stent thrombosis (odds ratio,
1.174, conﬁdence interval, 0.604 to 2.280). These ﬁndings are similar to the individual studies although other studies have noted
increased late loss with zotarolimus-eluting stents and this current data associated with late loss should be kept in mind when
makimgclinical decisions regarding sent selection.
1.Introduction
Managementofcoronarydiseasehasevolvedimmenselyover
the past 40 years. Coronary artery bypass grafting (CABG)
has become less common with the development of percu-
taneous coronary intervention (PCI). PCI has now become
standard of care for managing patients with myocardial
infarction (MI), with stenting techniques replacing balloon
angioplasty. The increased role of stenting has led to the
development of drug-eluting stents which have been shown
tolowerrestenosis rateswhen comparedto bare metal stents,
without increasing the risk of MI or death [1]. There are
various options when selecting drug-eluting stents, includ-
ing paclitaxel-, sirolimus, and zotarolimus-eluting stents.
With several options when it comes to drug-eluting stents,
the need for evidence-based guidelines has become evident.
This meta-analysis pools data from studies comparing 12-
month clinicaloutcomes of newer zotarolimus-eluting stents
to commonly used paclitaxel-eluting stents.
2.Methods
2.1. Literature Sources, Search Terms, and Study Selection.
Systematic review of medical literature was carried out
to identify studies evaluating outcomes after stenting with
zotarolimus- and paclitaxel-eluting stents. Studies were
collected by searching MEDLINE and the Cochrane Library
using web-based search engines such as OVID. All relevant
studies were assessed for inclusion regardless of time of2 ISRN Cardiology
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Figure 1: Overview of study selection.
Table 1: Summary of heterogeneity analysis.
Qd F P -value Result
MI 1.6724 3 .6431 Homogenous
MACE 3.1045 2 .2118 Homogenous
Cardiac death 0.8357 3 .8357 Homogenous
All-cause death 3.1045 2 .2118 Homogenous
Stent thrombosis 0.2858 3 .9627 Homogenous
Target vessel
revascularization 6.7677 3 .0797 Homogenous
Target lesion
revascularization 5.8443 2 .0538 Homogenous
dF: degrees of freedom.
publication. Search terms used include zotarolimus, pacli-
taxel, drug-eluting stents, stent thrombosis, stent outcomes,
and combinations of these terms. Hand search for articles,
abstracts, and reviews was also conducted using references
of already identiﬁed studies. Explicit inclusion and exclusion
criteria were used to evaluate the titles and abstracts from
collected articles on basis of the aforementioned criteria for
potential inclusion. Figure 1 outlines study selection.
2.2. End Points and Deﬁnitions. A total of seven end
points were extracted from ﬁve studies [2–6]. End points
studied were myocardial infarction (MI), major adverse
cardiac events (MACE), cardiac death, all-cause death, stent
thrombosis, target vessel revascularization, and target lesion
revascularization. Only studieswith corresponding endpoint
deﬁnitions were included.
2.3. Data Extraction and Quality Assessment. After articles
were collected and screened for inclusion, full articles were
retrieved for titles thought to fulﬁll inclusion criteria. Data
was then extracted while also scoring the methodological
quality of each study.
2.4. Statistical Analysis. Individual patient data from
included studies was not available, so a meta-analysis was
done using summary statistics from each. Statistical analysis
was performed using the MedCalcsoftware package(Version
11.3, Mariakerke, Belgium). Cochrane’s Q statistics were
calculated and used to determine the heterogeneity of the
studies for each end point. The end points demonstrated
homogeneous results so the ﬁxed eﬀects model was used for
analysis (Table 1). A two-sided alpha error less than 0.05
was considered to be statistically signiﬁcant. Heterogeneity
analysis is summarized in Table 1.
3.Results
3.1. Baseline Characteristics. The characteristics of each
individual trial had no signiﬁcant diﬀerences within stud-
ies (Table 2). Results of the meta-analysis are shown in
Figures 2, 3, 4, 5, 6, 7,a n d8.There were nosigniﬁcant diﬀer-
ences in patient demographics between both groups.
3.2. Myocardial Infarction. There was a signiﬁcant decrease
in risk of myocardial infarction in the zotarolimus group
(odds ratio, 0.250, conﬁdence interval, 0.160 to 0.392).
3.3. Major Adverse Cardiac Events. There was a slightly lower
riskofmajoradversecardiaceventsinthezotarolimusgroup;
this ﬁnding, however, is statistically insigniﬁcant (odds ratio,
0.813, conﬁdence interval, 0.656 to 1.007).
3.4. Cardiac Death. There was a slightly lower risk of cardiac
death in the zotarolimus group; this ﬁnding, however, is
statistically insigniﬁcant (odds ratio, 0.817, conﬁdence
interval, 0.359 to 1.857).
3.5. All-Cause Death. There was a slightly lower risk of all-
cause death in the zotarolimus group; this ﬁnding, however,
is statistically insigniﬁcant (odds ratio, 0.820, conﬁdence
interval, 0.443 to 1.516).
3.6. Stent Thrombosis. There was a slightly higher risk of
stent thrombosis in the zotarolimus group; this ﬁnding,
however, is statistically insigniﬁcant (odds ratio, 1.174, con-
ﬁdence interval, 0.604 to 2.280).
3.7. Target Vessel Revascularization. There was a signiﬁ-
cantly higher risk of target vessel revascularization in the
zotarolimus group (odds ratio, 1.336, conﬁdence interval,
1.003 to 1.778).
3.8. Target Lesion Revascularization. Risk of target lesion
was lower in the zotarolimus group; this ﬁnding, however,
is statistically insigniﬁcant (odds ratio, 0.936, conﬁdence
interval 0.702 to 1.247).ISRN Cardiology 3
Table 2: Baseline characteristics of patients in included studies.
Chevalier et al. Choi et al. Kim et al. Park et al. Leon et al.
Number studied
PES 197 153 105 884 775
ZES 199 86 47 883 773
Age
PES 63 +/− 11 61.54 +/− 12.22 63 +/− 9 62.0 +/− 9.6 63.6 +/− 11.0
Zes 63 +/− 10 60.24 +/− 11.76 59 +/− 12 61.7 +/− 9.3 63.5 +/− 11.1
Gender (male)
PES 77% 100 (65.4%) 76 (72.4%) 582 (65.8%) 531 (68.5%)
ZES 75% 69 (80.2%) 37 (78.7%) 586 (66.4%) 517 (66.9%)
Vessel location (LAD)
PES 40% 72 (47.1%) 45 (42.9%) 611 (50.7%) 321 (41.5%)
ZES 48% 45 (52.3%) 30 (63.8%) 622 (52.3%) 326 (42.2%)
Vessel location (LCx)
PES 19% 29 (19.0%) 15 (14.2%) 253 (21.0) 202 (26.1%)
ZES 24% 10 (11.6%) 2 (4.3%) 252 (21.2%) 208 (26.9%)
Vessel location (RCA)
PES 41% 52 (34.0%) 45 (42.9) 340 (28.2%) 251 (32.4%)
ZES 28% 31 (36.0%) 15 (31.9%) 316 (26.6) 238 (30.8%)
Diabetes mellitus
PES 26% 104 (68.0%) 23 (21.9%) 245 (27.7%) 236 (30.5%)
ZES 22% 64 (74.4%) 12 (25.5%) 268 (30.4%) 241 (31.2%)
Hypertension
PES 67% 86 (56.2%) 50 (47.6%) 540 (61.1%) 640 (82.6%)
ZES 69% 53 (61.6%) 20 (43.5%) 552 (62.5%) 614 (79.4%)
Hyperlipidemia
PES 72% 104 (68.2%) 43 (41.3%) 446 (50.5%) 657 (84.8%)
ZES 78% 57 (66.3%) 18 (39.1%) 466 (52.8%) 629 (81.4)
PES: paclitaxel-eluting stent; ZES: zotarolimus-eluting stent; LAD: left anterior descending coronary artery; LCx: left circumﬂex coronary artery; RCA: right
coronary artery.
4.Discussion
This meta-analysis shows that zotarolimus-eluting stents
may not diﬀer with respect to outcomes studied here. Other
studies have had similar results with these particular out-
comes when comparing zotarolimus- and paclitaxel-eluting
stents [3–5]. A two-year follow-up study by Cicek et al.,
however,didﬁndastatistically signiﬁcant decreaseinMACE,
coronary artery bypass graft, and Qwave MI, associated with
zotarolimus-eluting stents when compared to paclitaxel-
eluting stents. No major diﬀerences were reported by this
study for all-cause death, target vessel revascularization,
and non-target-vessel revascularization [7]. This study was
nonrandomized and had a small number of patients; so
the true value of these ﬁndings is questionable. Where the
two stent varieties do seem to diﬀer is in late loss, an
end point not included in this 12-month outcome meta-
analysis. Zotarolimus-eluting stents have been documented
to demonstrate greater late loss than paclitaxel-eluting stents
[2,3,8].This study,however,didnotﬁnd anincrease instent
thrombosis with zotarolimus-eluting stents.
Drug-eluting stents have signiﬁcantly reduced the rate
of restenosis when compared to bare metal stents [9]a n d
have assumed a larger role in the management of STEMI
as primary percutaneous coronary intervention has become
standard of care. When compared to bare metal stents, drug-
eluting stents have shown greater 1-year event-free survival
rates [10–12] and similar safety proﬁles [13, 14]i nS T E M I
patients. Sirolimus- and paclitaxel-eluting stents have been
used with success for primary PCI in standard STEMI cases
as well as those complicated by anatomical variations [15].
The ENDEAVOR IV trial studied the cost-eﬀectiveness
of zotarolimus-eluting stents and concluded that cost-
eﬀectiveness was similar to that of paclitaxel-eluting stents.
Analysistookinto accountquality-adjustedsurvival, medical
costs, and relative cost-cost eﬀectiveness [16].
While zotarolimus-eluting stents have been associated
with greater in-stent late loss when compared to paclitaxel-
eluting stents, this may not have much clinical impact as
studies have noted that low mean values of in-stent late loss
are not associated with the risk of stent thrombosis [17].4 ISRN Cardiology
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Figure 2: Forest plot comparing risk of myocardial infarction.
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Figure 3: Forest plot comparing risk of major adverse cardiac
events.
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Figure 4: Forest plot comparing risk of cardiac death.
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Figure 5: Forest plot comparing risk of all-cause mortality.
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Figure 6: Forest plot comparing risk of stent thrombosis.
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Figure 7: Forest plot comparing risk of target vessel revasculariza-
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Figure 8: Forest plot comparing risk of target lesion revasculariza-
tion.
Limitations of this meta-analysis include those inherent
to all such analyses such as pooling of data from studies
which may have slightly diﬀering designs and heterogeneity.
ItshouldalsobenotedthatZoMaxxIincludedonly9-month
follow-up data which was included in this study. As with
any meta-analysis, publication and selection bias may have
impacted results of this analysis.
5.Conclusion
The zotarolimus-eluting stents oﬀer a safe option when
selecting a drug-eluting stent. When compared to paclitaxel-
eluting stents, zotarolimus eluting stents are associated with
a signiﬁcantly lower risk of myocardial infarction while
being associated with a signiﬁcantly higher risk of need
for target vessel revascularization. Additionally, studies have
shown increased late loss in zotarolimus-eluting stents when
compared to paclitaxel-elutingstents. This increased late loss
should be kept in mind when zotarolimus-eluting stents are
being considered. Comparison of 12-month outcomes does
not seem to warrant the use of either stent over the other,
particularly keeping in mind the absence of any advantage
aﬀorded by one stent in regards to cost-eﬀectiveness.
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